Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
Launched by DR. DANIELLE VICUS · Feb 21, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on screening for anal cancer in women who have been diagnosed with certain vulvar conditions, specifically those with high-grade vulvar dysplasia or vulvar cancer. Researchers believe that many women with these conditions may also have abnormal cells in the anal area, which could lead to anal cancer. The study aims to find out how common these abnormal cells are by performing anal Pap smears and additional tests on women over 40 who meet specific criteria. If successful, this research could help establish regular screening for anal cancer in women with vulvar issues, improving early detection and treatment options.
To be eligible for this study, women need to be 40 years or older and have a prior diagnosis of vulvar cancer or a high-grade vulvar condition called VIN 2/3. Women with certain medical conditions, such as HIV or those taking medications that weaken the immune system, are not eligible. Participants can expect to undergo anal Pap smears and possibly further examinations if any abnormalities are found. This trial is currently recruiting participants and aims to improve health policies regarding anal cancer screening for women in similar situations.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women age ≥ 40
- • Previous diagnosis of VIN 2/3 or vulvar
- Exclusion Criteria:
- • Women with a previous diagnosis of cancer aside from basal cell carcinoma of the skin, cervical cancer, or vulvar cancer
- • Women who are HIV positive
- • Women currently taking immunosuppressant medication
- • Women who have had a previous hysterectomy
About Dr. Danielle Vicus
Dr. Danielle Vicus is a distinguished clinical trial sponsor recognized for her commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and a passion for innovative therapies, Dr. Vicus leads and oversees a range of clinical trials aimed at developing groundbreaking treatments across various therapeutic areas. Her dedication to ethical research practices and patient safety ensures that each study is conducted with the highest standards of integrity and compliance. Dr. Vicus collaborates with multidisciplinary teams and regulatory bodies to foster innovation while prioritizing the well-being of participants, making her a pivotal figure in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Danielle Vicus, MD
Principal Investigator
Odette Cancer Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials